However, even for gliomas with methylated MGMT promoters, a large number of patients are still non-responding to TMZ treatment, indicating that a high MGMT level cannot cover all mechanism for the TMZ responsiveness [9, 10]. The gene discussed is MGMT; the disease is central nervous system cancer.